drugset
drugset / Trial / NCT01238679

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers

NCT01238679 ↗

Phase 1 Terminated 20 enrolled Biogen
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this study evaluates the safety and tolerability of multiple, escalating doses of PF-04958242 administered orally to healthy adult participants.This study also evaluates the plasma and urine multiple dose pharmacokinetics (PK) of PF-04958242.

Timeline

Start
2010-11-24
Primary completion
2011-05-03
Completion
2011-05-03

Drugs

EvaluationDrugModalityDoseRoute
Subject PESAMPATOR Small molecule 0.03 mg Oral
Subject PESAMPATOR Small molecule 0.05 mg Oral
Subject PESAMPATOR Small molecule 0.1 mg Oral
Subject PESAMPATOR Small molecule 0.15 mg Oral
Subject PESAMPATOR Small molecule 0.2 mg Oral
Subject PESAMPATOR Small molecule 0.25 mg Oral

Indications

No indication recorded.